|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung JJ, Lau JY, Goh KL and Leung WK: Asia
Pacific Working Group on Colorectal Cancer: Increasing incidence of
colorectal cancer in Asia: Implications for screening. Lancet
Oncol. 6:871–876. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li M and Gu J: Changing patterns of
colorectal cancer in China over a period of 20 years. World J
Gastroenterol. 11:4685–4688. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Henaine AM, Chahine G, Salameh P, Elias E,
Massoud M, Hartmann D, Aulagner G and Armoiry X: MANAGEMENT OF
METASTATIC COLORECTAL CANCER: Current Treatments and New Therapies.
J Med Liban. 63:218–227. 2015.PubMed/NCBI
|
|
6
|
Kozovska Z, Gabrisova V and Kucerova L:
Colon cancer: Cancer stem cells markers, drug resistance and
treatment. Biomed Pharmacother. 68:911–916. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Temraz S, Mukherji D, Alameddine R and
Shamseddine A: Methods of overcoming treatment resistance in
colorectal cancer. Crit Rev Oncol Hematol. 89:217–230. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dai Z, Huang Y and Sadee W: Growth factor
signaling and resistance to cancer chemotherapy. Curr Top Med Chem.
4:1347–1356. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schickel R, Boyerinas B, Park SM and Peter
ME: MicroRNAs: Key players in the immune system, differentiation,
tumorigenesis and cell death. Oncogene. 27:5959–5974. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang
B, Shu Y and Liu P: miR-497 modulates multidrug resistance of human
cancer cell lines by targeting BCL2. Med Oncol. 29:384–391. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang T, Zheng ZM, Li XN, Li ZF, Wang Y,
Geng YF, Bai L and Zhang XB: MiR-223 modulates multidrug resistance
via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp
Biol Med (Maywood). 238:1024–1032. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xia H and Hui KM: Mechanism of cancer drug
resistance and the involvement of noncoding RNAs. Curr Med Chem.
21:3029–3041. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zong C, Wang J and Shi TM: MicroRNA 130b
enhances drug resistance in human ovarian cancer cells. Tumour
Biol. 35:12151–12156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Barbarotto E, Schmittgen TD and Calin GA:
MicroRNAs and cancer: Profile, profile, profile. Int J Cancer.
122:969–977. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Osada H and Takahashi T: MicroRNAs in
biological processes and carcinogenesis. Carcinogenesis. 28:2–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen CZ: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cho WC: OncomiRs: The discovery and
progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xue J, Niu J, Wu J and Wu ZH: MicroRNAs in
cancer therapeutic response: Friend and foe. World J Clin Oncol.
5:730–743. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fang L, Li H, Wang L, Hu J, Jin T, Wang J
and Yang BB: MicroRNA-17-5p promotes chemotherapeutic drug
resistance and tumour metastasis of colorectal cancer by repressing
PTEN expression. Oncotarget. 5:2974–2987. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li
K, Zhou L, Sun Y, Li M, Zhou J, et al: miR-508-5p regulates
multidrug resistance of gastric cancer by targeting ABCB1 and
ZNRD1. Oncogene. 33:3267–3276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rasmussen MH, Jensen NF, Tarpgaard LS,
Qvortrup C, Rømer MU, Stenvang J, Hansen TP, Christensen LL,
Lindebjerg J, Hansen F, et al: High expression of microRNA-625-3p
is associated with poor response to first-line oxaliplatin based
treatment of metastatic colorectal cancer. Mol Oncol. 7:637–646.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu K, Liang X, Cui D, Wu Y, Shi W and Liu
J: miR-1915 inhibits Bcl-2 to modulate multidrug resistance by
increasing drug-sensitivity in human colorectal carcinoma cells.
Mol Carcinog. 52:70–78. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sui H, Cai GX, Pan SF, Deng WL, Wang YW,
Chen ZS, Cai SJ, Zhu HR and Li Q: miR200c attenuates P-gp-mediated
MDR and metastasis by targeting JNK2/c-Jun signaling pathway in
colorectal cancer. Mol Cancer Ther. 13:3137–3151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liao H, Bai Y, Qiu S, Zheng L, Huang L,
Liu T, Wang X, Liu Y, Xu N, Yan X and Guo H: MiR-203 downregulation
is responsible for chemoresistance in human glioblastoma by
promoting epithelial-mesenchymal transition via SNAI2. Oncotarget.
6:8914–8928. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C,
Quan L, Bai J and Xu N: Suppression of p21 by c-Myc through members
of miR-17 family at the post-transcriptional level. Int J Oncol.
37:1315–1321. 2010.PubMed/NCBI
|
|
31
|
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim
JH, Kim JW and Kim S: MicroRNA expression profiles in serous
ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim YK, Yu J, Han TS, Park SY, Namkoong B,
Kim DH, Hur K, Yoo MW, Lee HJ, Yang HK and Kim VN: Functional links
between clustered microRNAs: Suppression of cell-cycle inhibitors
by microRNA clusters in gastric cancer. Nucleic Acids Res.
37:1672–1681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou J, Zhou Y, Yin B, Hao W, Zhao L, Ju W
and Bai C: 5-Fluorouracil and oxaliplatin modify the expression
profiles of microRNAs in human colon cancer cells in vitro. Oncol
Rep. 23:121–128. 2010.PubMed/NCBI
|
|
34
|
Yu XF, Zou J, Bao ZJ and Dong J: miR-93
suppresses proliferation and colony formation of human colon cancer
stem cells. World J Gastroenterol. 17:4711–4717. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu S, Patel SH, Ginestier C, Ibarra I,
MartinTrevino R, Bai S, McDermott SP, Shang L, Ke J, Ou SJ, et al:
MicroRNA93 regulates proliferation and differentiation of normal
and malignant breast stem cells. PLoS Genet. 8:e10027512012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fu X, Tian J, Zhang L, Chen Y and Hao Q:
Involvement of microRNA-93, a new regulator of PTEN/Akt signaling
pathway, in regulation of chemotherapeutic drug cisplatin
chemosensitivity in ovarian cancer cells. FEBS Lett. 586:1279–1286.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu ZB, Li WQ, Lin SJ, Wang CD, Cai L, Lu
JL, Chen YX, Su ZP, Shang HB, Yang WL, et al: MicroRNA expression
profile of bromocriptine-resistant prolactinomas. Mol Cell
Endocrinol. 395:10–18. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C (T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhu H, Cai C and Chen J: Suppression of
P-glycoprotein gene expression in Hs578T/Dox by the overexpression
of caveolin-1. FEBS Lett. 576:369–374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J,
Jiang B, Shu Y and Liu P: miR-200bc/429 cluster modulates multidrug
resistance of human cancer cell lines by targeting BCL2 and XIAP.
Cancer Chemother Pharmacol. 69:723–731. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Harper JW, Adami GR, Wei N, Keyomarsi K
and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent
inhibitor of G1 cyclin-dependent kinases. Cell. 75:805–816. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xiong Y, Hannon GJ, Zhang H, Casso D,
Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin
kinases. Nature. 366:701–704. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tang Q, Zou Z, Zou C, Zhang Q, Huang R,
Guan X, Li Q, Han Z, Wang D, Wei H, et al: MicroRNA-93 suppress
colorectal cancer development via Wnt/β-catenin pathway
downregulating. Tumour Biol. 36:1701–1710. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chai H, Liu M, Tian R, Li X and Tang H:
miR-20a targets BNIP2 and contributes chemotherapeutic resistance
in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta
Biochim Biophys Sin (Shanghai). 43:217–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Baguley BC: Multiple drug resistance
mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yu X, Li Z, Yu J, Chan MT and Wu WK:
MicroRNAs predict and modulate responses to chemotherapy in
colorectal cancer. Cell Prolif. 48:503–510. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Valeri N, Gasparini P, Braconi C, Paone A,
Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, et al:
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating
human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA.
107:21098–21103. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang L, Pickard K, Jenei V, Bullock MD,
Bruce A, Mitter R, Kelly G, Paraskeva C, Strefford J, Primrose J,
et al: miR-153 supports colorectal cancer progression via
pleiotropic effects that enhance invasion and chemotherapeutic
resistance. Cancer Res. 73:6435–6447. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang Z: The guideline of the design and
validation of miRNA mimics. Methods Mol Biol. 676:211–223. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhu H, Wu H, Liu X, Evans BR, Medina DJ,
Liu CG and Yang JM: Role of MicroRNA miR-27a and miR-451 in the
regulation of MDR1/P-glycoprotein expression in human cancer cells.
Biochem Pharmacol. 76:582–588. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z,
Liu J, Cui Y, Bian X, Bie P and Qian C: MicroRNA-122 sensitizes HCC
cancer cells to adriamycin and vincristine through modulating
expression of MDR and inducing cell cycle arrest. Cancer Lett.
310:160–169. 2011.PubMed/NCBI
|
|
52
|
Bao L, Hazari S, Mehra S, Kaushal D, Moroz
K and Dash S: Increased expression of P-glycoprotein and
doxorubicin chemoresistance of metastatic breast cancer is
regulated by miR-298. Am J Pathol. 180:2490–2503. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Munoz JL, Bliss SA, Greco SJ, Ramkissoon
SH, Ligon KL and Rameshwar P: Delivery of functional anti-miR-9 by
mesenchymal stem cell-derived exosomes to glioblastoma multiforme
cells conferred chemosensitivity. Mol Ther Nucleic Acids.
2:e1262013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tomida A and Tsuruo T: Drug resistance
mediated by cellular stress response to the microenvironment of
solid tumors. Anticancer Drug Des. 14:169–177. 1999.PubMed/NCBI
|
|
55
|
Huang L, Ao Q, Zhang Q, Yang X, Xing H, Li
F, Chen G, Zhou J, Wang S, Xu G, et al: Hypoxia induced paclitaxel
resistance in human ovarian cancers via hypoxia-inducible factor
1alpha. J Cancer Res Clin Oncol. 136:447–456. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Warfel NA and El-Deiry WS: p21WAF1 and
tumourigenesis: 20 years after. Curr Opin Oncol. 25:52–58. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ding Y, Wang Y, Chen J, Hu Y, Cao Z, Ren P
and Zhang Y: p21 overexpression sensitizes osteosarcoma U2OS cells
to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade. Tumour
Biol. 35:3119–3123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Qin LF and Ng IO: Exogenous expression of
p21 (WAF1/CIP1) exerts cell growth inhibition and enhances
sensitivity to cisplatin in hepatoma cells. Cancer Lett. 172:7–15.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Abukhdeir AM, Vitolo MI, Argani P, De
Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP,
Pendleton C, et al: Tamoxifen-stimulated growth of breast cancer
due to p21 loss. Proc Natl Acad Sci USA. 105:288–293. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ziller C, Lincet H, Muller CD, Staedel C,
Behr JP and Poulain L: The cyclin-dependent kinase inhibitor p21
(cip1/waf1) enhances the cytotoxicity of ganciclovir in HSV-tk
transfected ovarian carcinoma cells. Cancer Lett. 212:43–52. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ivanovska I, Ball AS, Diaz RL, Magnus JF,
Kibukawa M, Schelter JM, Kobayashi SV, Lim L, Burchard J, Jackson
AL, et al: MicroRNAs in the miR-106b family regulate p21/CDKN1A and
promote cell cycle progression. Mol Cell Biol. 28:2167–2174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li Z, Yang CS, Nakashima K and Rana TM:
Small RNA-mediated regulation of iPS cell generation. EMBO J.
30:823–834. 2011. View Article : Google Scholar : PubMed/NCBI
|
